Workiva Announces Julie Iskow as Chief Executive Officer
Workiva Inc. (NYSE: WK), the company powering transparent reporting for a better world, announced today that Julie Iskow, current President and Chief Operating Officer, has been appointed to succeed Marty Vanderploeg as Chief Executive Officer, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005356/en/
Workiva Inc. (NYSE: WK) Announces Julie Iskow as Chief Executive Officer (Photo: Business Wire)
Current Board Chair and prospective Lead Independent Director Dave Mulcahy said, “The Board is delighted to appoint Julie Iskow to Chief Executive. She is a strong, respected, and values-driven leader with an impressive and proven track record of delivering consistent high-quality performance through her relentless commitment to our customers and to our people. Julie has played an instrumental role in Workiva’s success over the last three years. She is an engineer, technologist, and strategic operator, whose innovation-first mindset has created a differentiated product offering and sustainable rigor around Workiva’s platform and solutions. The Board is confident in Julie’s ability to lead Workiva through its next stage of growth.”
Of her new role, Iskow said, “Workiva is one of the most relevant and innovative technology companies of our time. We have a transformative platform, unbridled potential, and an enduring foundation on which to build our future. I consider it a distinct privilege to succeed Marty and work with our incredibly talented team to move Workiva’s legacy forward into our next phase of growth and impact.”
Mulcahy said, “We would like to thank Marty for his steadfast leadership. During his tenure, he transformed Workiva into the leading multi-solution platform company for assured integrated business reporting, serving 5,600 customers across the globe. Marty has been an exceptional leader for Workiva, championing an employee culture of progress, product innovation, customer focus, and achieving strong shareholder value. We look forward to working with him in his expanded Board leadership role.”
“As a co-founder of Workiva, I have had the good fortune of working with a talented team for the past 15 years, five of those as CEO,” said Vanderploeg. “Now is the right time for me, and for Workiva, to make this change. Since day one of Julie’s arrival, she’s made our organization better. Julie has spent the past three years thoughtfully building and shaping our remarkable leadership team and operational strategy as we progress toward a long-term goal of $1 billion in revenue. I look forward to supporting her in my new role as Non-Executive Chair.”
About Julie Iskow
Julie Iskow joined Workiva in 2019 as EVP and Chief Operating Officer. She has extensive experience scaling enterprise SaaS companies with strong, profitable growth and has a robust background in product development and optimizing operations. Iskow was promoted to President and Chief Operating Officer in March 2022 and has been overseeing day-to-day operations with global responsibility for technology, product, sales, partners, marketing, services, and customer and partner experience. This transition allows her and the Workiva team to continue with their excellence in execution.
Before joining Workiva, Iskow served as EVP and Chief Technology Officer at Medidata Solutions, creator of cutting-edge SaaS technology and analytics solutions for life sciences. Prior to Medidata, she was the Senior Vice President of Product Development and Chief Information Officer at WageWorks, a SaaS platform for consumer directed benefits solutions. Before WageWorks, she spent over a decade in engineering and technology leadership positions, responsible for automation and robotics software used in high-tech manufacturing.
She currently serves on the board of directors of Workiva Inc. and Five9, a leading provider of cloud software for contact centers. She has a bachelor of science degree from the University of California, Berkeley and a master of science degree from the University of California, Davis.
About Workiva
Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva
Follow Workiva on Twitter: www.twitter.com/workiva
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005356/en/
Contact information
Investor Inquiries:
Mike Rost
investor@workiva.com
(515) 663-4493
Media Inquiries:
Darcie Brossart
press@workiva.com
(515) 663-4471
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom